A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150
Latest Information Update: 06 May 2022
Price :
$35 *
At a glance
- Drugs MK 8150 (Primary)
- Indications Hypertension
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms MK-8150-002
- Sponsors Merck Sharp & Dohme
- 18 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Feb 2013 Actual initiation date changed from Jul 2012 to Aug 2012 as reported by ClinicalTrials.gov.